Otonomy, Inc. is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The Company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss and tinnitus. The Company currently offers OTIPRIO, a single-dose ciprofloxacin, for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement. Otonomy’s lead clinical program, OTIVIDEX, is a steroid in development for the treatment of Ménière’s disease. Otonomy’s second clinical program, OTO-313, is a sustained-exposure formulation of gacyclidine in development for the treatment of tinnitus. Otonomy’s third clinical program, OTO-413, is a sustained-exposure formulation of BDNF in development for the repair of cochlear synaptopathy, an underlying cause of hearing loss.